Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004956 | 0.87 | HRH3 (0.44) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL1004793 | 0.79 | HRH4 (0.48) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL1392811 | 0.79 | HRH4 (0.51) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL1005108 | 0.78 | HRH3 (0.43) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL17575660 | 0.77 | HRH4 (0.50) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL21310107 | 0.77 | HRH4 (0.50) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL22509467 | 0.77 | HRH4 (0.50) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL24851409 | 0.77 | HRH4 (0.50) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL975741 | 0.75 | HRH3 (0.46) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL13562340 | 0.75 | HRH3 (0.43) | KDM4EALDH1A1HPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004902-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119925375-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930630-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-115151535-B | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4107154-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| CN-115151535-A | Heteroaryl heterocyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A4, CYP4B1, CYP3A5 | KDM4E 1963/4885ALDH1A1 1919/4885HPGD 1128/4885 |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | BTK, SYK, LCK | KDM4E 292/4885ALDH1A1 3619/4885HPGD 3337/4885 |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP11B2 | KDM4E 3801/4885ALDH1A1 425/4885HPGD 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.